GeneDx Holdings Corp. Cash Flow Statement
WGS / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
GeneDx Holdings Corp. generated $33M in operating cash flow and $14M in free cash flow in FY2025. Free cash flow margin was 3.3% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$21.0M | -$52.3M | -$175.8M | -$549.0M | -$245.4M | -$241.3M | -$29.7M |
| Depreciation & Amortization | $9.6M | $7.9M | $19.7M | $50.0M | $21.8M | $11.7M | $6.4M |
| Operating Cash Flow | $33.3M | -$28.5M | -$180.1M | -$319.2M | -$190.4M | -$93.1M | -$18.7M |
| Capital Expenditures | $19.0M | $5.5M | $5.3M | $7.2M | $9.4M | $24.1M | $11.9M |
| Free Cash Flow | $14.3M | -$34.0M | -$185.4M | -$326.3M | -$199.8M | -$117.2M | -$30.7M |
| FCF Margin | 3.3% | -11.1% | -91.5% | -139.0% | -94.2% | - | -15.6% |